This article is more than 5 years old. Information may no longer be current.
Gelatine matrix with human thrombin reduced blood loss in posterior AIS surgery
Click Here to Manage Email Alerts
COPENHAGEN, Denmark — The use of gelatine matrix with human thrombin in adolescent patients who underwent posterior spinal fusion for idiopathic scoliosis was shown in results of a randomized clinical trial presented at the EuroSpine Annual Meeting, here, to reduce intraoperative blood loss and postoperative hemoglobin loss.
The paper was selected as one of the “Best of Show” studies presented at the meeting.
According to Ilkka J. Helenius, MD, PhD, of Turku, Finland, patients in the study who received two to four units of gelatin matrix with human thrombin (Floseal Matrix 5 mL, Baxter) lost less blood and hemoglobin postoperatively than similar surgical patients treated with traditional hemostatic methods.
“I can conclude the use of gelatine matrix with human thrombin decreased intraoperative and postoperative blood loss when added to traditional surgical hemostasis techniques,” Helenius said.
Sixty adolescent patients who were about 15 or 16 years old were randomized 1:1 into a traditional or control group (C) and a treatment group which received the gelatine matrix with human thrombin (T).
The patients’ mean curves were 55° in the C group and 53° in the T group, however the control patients’ main thoracic curves were significantly less flexible on bending radiographs.
As for blood loss, every added operative hour significantly increased the intraoperative blood loss by 357 mL and total blood loss by 431 mL, according to Helenius. However, when the investigators adjusted for operative time and number of pedicle instruments used, intraoperative blood loss significantly decreased 171 mL in group T compared to group C.
The total blood loss in group T also decreased significantly 177 mL after the intervention was used.
Hemoglobin loss at 2 days postoperatively vs. one day preoperative was significantly less in group T vs. group C (P = .013), according to Helenius. – by Robert Linnehan
Reference: Helenius IJ, et al. Paper #75. Presented at: EuroSpine Annual Meeting; Sept. 2-4, 2015; Copenhagen, Denmark.
Disclosure: Helenius reports receiving grants/research support from Medtronic and Baxter. He reports he is a consultant for Medtronic and DePuy Synthes.